New cocktail targets Hard-to-Treat myeloma
NCT ID NCT05560399
First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This early-phase study tests a three-drug combination (iberdomide, elotuzumab, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find a safe dose and see if the combo can shrink tumors. About 37 adults will take part, starting with a small group to check safety, then a larger group at the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.